ZO Skin Health - Brightalive
Non-retinol brightening with tranexamic acid, niacinamide, and peptide drone technology
About This Treatment
Brightalive is ZO's innovative brightening product without retinol or hydroquinone.
■ Intelligent Peptide Drone Technology: encapsulated peptides delivered precisely to target melanocytes. ■ Tranexamic acid: blocks UV-induced melanin signaling via plasmin inhibition. ■ Niacinamide: inhibits melanosome transfer and promotes ceramide synthesis.
Suitable for retinol-intolerant patients and during pregnancy.
Mechanism of Action
Peptide drone technology delivers peptides via liposome-like nanocapsules selectively to melanocyte MC1R receptors. Tranexamic acid inhibits plasmin, blocking the UV→arachidonic acid→prostaglandin→melanin synthesis cascade upstream. Niacinamide inhibits melanosome transfer to keratinocytes by 35-68% (5% for 8 weeks). Three synergistic mechanisms for multi-target pigmentation control.
Indications
Expected Results
15-week physician-led study (50 subjects, ages 30-70, Fitzpatrick I-VI): 50% improvement in skin appearance. 16-week follow-up showed significant improvements in mild to severe dyschromia.
Clinical Evidence
Risks & Side Effects
Very low risk. Rare transient mild redness/irritation. No photosensitivity risk as hydroquinone/retinol-free. Sunscreen recommended.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition